The antibacterial effect of a proline-rich antibacterial peptide A3-APO

Current Medicinal Chemistry

Volumn 16, Issue 30, 2009, Pages 3996-4002

  Rozgonyi, F ^a,b   Szabo, D ^a   Kocsis, B ^a   Ostorhazi E ^b   Abbadessa, G ^c   Cassone, M ^c   Wade, J D ^d   Otvos Jr , L ^e  

^a SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c TEMPLE UNIVERSITY   (United States)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e Temple University   (United States)

Author keywords

Bacterial membrane; Dnak; Proline rich antibacterial peptides; Protein folding inhibitor; Resistance; Synergy

Indexed keywords

AMOXICILLIN; CHLORAMPHENICOL; CIPROFLOXACIN; COTRIMOXAZOLE; DIMER; DRUG METABOLITE; IMIPENEM; MONOMER; PEPTIDE A3 APO; POLYPEPTIDE ANTIBIOTIC AGENT; SULFONAMIDE; TRIMETHOPRIM; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; BACTEREMIA; BACTERIAL INFECTION; BACTERIAL MEMBRANE; BIOAVAILABILITY; BLEEDING; CATHETER INFECTION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DEGRADATION; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG PENETRATION; DRUG POTENTIATION; DRUG STRUCTURE; ENTEROBACTERIACEAE; GRAM NEGATIVE INFECTION; HEMOLYSIS; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; NONHUMAN; POSTANTIBIOTIC EFFECT; PROTEIN STABILITY; REVIEW; SEPSIS; STRUCTURE ACTIVITY RELATION; TOXICITY TESTING; URINARY TRACT INFECTION;

AMINO ACID SEQUENCE; ANIMALS; ANTI-BACTERIAL AGENTS; DRUG DESIGN; MICROBIAL SENSITIVITY TESTS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PEPTIDES; PROLINE;

EID: 70450176418     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986709789352295     Document Type: Review

References (43)

1. Levy, S.B.; Marshall, B. Antibacterial resistance worldwide: causes, challenges and responses. Nat. Med., 2004, 10, S122-129. (Pubitemid 40018235)
2. Otvos, L., Jr.; Wade, J.D.; Lin, F.; Condie, B.A.; Hanrieder, J.; Hoffmann, R. Designer antibacterial peptides kill fluoroquinolone-resistant clinical isolates. J. Med. Chem., 2005, 48, 5349-5359. (Pubitemid 41114906)
3. Bush, K.; Macielag, M.; Weidner-Wells, M. Taking inventory: antibacterial agents currently at or beyond phase 1. Curr. Opin. Microbiol., 2004, 7, 466-476. (Pubitemid 39297126)
4. Zasloff, M. Antimicrobial peptides of multicellular organisms. Nature, 2002, 415, 389-395.
5. Cudic, M.; Condie, B.A.; Weiner, D.J.; Lysenko, E.S.; Xiang, Z.Q.; Insug, O.; Bulet, P.; Otvos, L., Jr. Development of novel antibacterial peptides that kill resistant isolates. Peptides, 2002, 23, 2071-2083.
6. Palffy, R.; Gardlik, R.; Behuliak, M.; Kadasi, L.; Turna, J.; Celec, P. On the physiology and pathophysiology of antimicrobial peptides. Mol. Med., 2009, 15, 51-59.
7. Brogden, K.A. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat. Rev. Microbiol., 2005, 3, 238-250.
8. Otvos, L., Jr. Antibacterial peptides and proteins with multiple cellular targets. J. Pept. Sci., 2005, 11, 697-706. (Pubitemid 41684256)
9. Uyterhoeven, E.T.; Butler, C.H.; Ko, D.; Elmore, D.E. Investigating the nucleic acid interactions and antimicrobial mechanism of buforin II. FEBS Lett., 2008, 582, 1715-1718.
10. Markossian, K.A.; Zamyatnin, A.A.; Kurganov, B.I. Antibacterial proline-rich oligopeptides and their target proteins. Biochemistry (Mosc), 2004, 69, 1082-1091.
11. Bulet, P.; Dimarcq, J.L.; Hetru, C.; Lagueux, M.; Charlet, M.; Hegy, G.; Van Dorsselaer, A.; Hoffmann, J.A. A novel inducible antibacterial peptide of Drosophila carries an O-glycosylated substitution. J. Biol. Chem., 1993, 268, 14893-14897. (Pubitemid 23206636)
12. Bulet, P.; Hegy, G.; Lambert, J.; van Dorsselaer, A.; Hoffmann, J.A.; Hetru, C. Insect immunity. The inducible antibacterial peptide diptericin carries two O-glycans necessary for biological activity. Biochemistry, 1995, 34, 7394-7400.
13. Hoffmann, R.; Bulet, P.; Urge, L.; Otvos, L., Jr. Range of activity and metabolic stability of synthetic antibacterial glycopeptides from insects. Biochim. Biophys. Acta, 1999, 1426, 459-467.
14. McManus, A.M.; Otvos, L., Jr.; Hoffmann, R.; Craik, D.J. Conformational studies by NMR of the antimicrobial peptide, drosocin, and its non-glycosylated derivative: effects of glycosylation on solution conformation. Biochemistry, 1999, 38, 705-714. (Pubitemid 129502116)
15. Gobbo, M.; Biondi, L.; Filira, F.; Gennaro, R.; Benincasa, M.; Scolaro, B.; Rocchi, R. Antimicrobial peptides: synthesis and antibacterial activity of linear and cyclic drosocin and apidaecin 1b analogues. J. Med. Chem., 2002, 45, 4494-4504.
16. Cudic, M.; Lockatell, C.V.; Johnson, D.E.; Otvos, L., Jr. In vitro and in vivo activity of an antibacterial peptide analog against uropathogens. Peptides, 2003, 24, 807-820. (Pubitemid 37011427)
17. Otvos, J., L.; Snyder, C.; Condie, B., A.; Bulet, P.; Wade, J., D. Chimeric antimicrobial peptides exhibit multiple modes of action. Int. J. Pept. Res. Ther. , 2005, 11, 29-42. (Pubitemid 41557306)
18. Kragol, G.; Lovas, S.; Varadi, G.; Condie, B.A.; Hoffmann, R.; Otvos, L., Jr. The antibacterial peptide pyrrhocoricin inhibits the ATPase actions of DnaK and prevents chaperone-assisted protein folding. Biochemistry, 2001, 40, 3016-3026. (Pubitemid 32206189)
19. Bikker, F.J.; Kaman-van Zanten, W.E.; de Vries-van de Ruit, A.M.; Voskamp-Visser, I.; van Hooft, P.A.; Mars-Groenendijk, R.H.; de Visser, P.C.; Noort, D. Evaluation of the antibacterial spectrum of drosocin analogues. Chem. Biol. Drug Des., 2006, 68, 148-153. (Pubitemid 44630331)
20. Cassone, M.; Vogiatzi, P.; La Montagna, R.; De Olivier Inacio, V.; Cudic, P.; Wade, J.D.; Otvos, L., Jr. Scope and limitations of the designer proline-rich antibacterial peptide dimer, A3-APO, alone or in synergy with conventional antibiotics. Peptides, 2008, 29, 1878-1886.
21. Kragol, G.; Hoffmann, R.; Chattergoon, M.A.; Lovas, S.; Cudic, M.; Bulet, P.; Condie, B.A.; Rosengren, K.J.; Montaner, L.J.; Otvos, L., Jr. Identification of crucial residues for the antibacterial activity of the proline-rich peptide, pyrrhocoricin. Eur. J. Biochem., 2002, 269, 4226-4237. (Pubitemid 35026009)
22. Otvos, L., Jr.; de Olivier Inacio, V.; Wade, J.D.; Cudic, P. Prior antibacterial peptide-mediated inhibition of protein folding in bacteria mutes resistance enzymes. Antimicrob. Agents Chemother., 2006, 50, 3146-3149. (Pubitemid 44396423)
23. Noto, P.B.; Abbadessa, G.; Cassone, M.; Mateo, G.D.; Agelan, A.; Wade, J.D.; Szabo, D.; Kocsis, B.; Nagy, K.; Rozgonyi, F.; Otvos, L., Jr. Alternative stabilities of a proline-rich antibacterial peptide in vitro and in vivo. Protein Sci., 2008, 17, 1249-1255.
24. Klootwijk, W.; Sleddens-Linkels, E.; de Boer, R.; Jansen, C.A.; Autar, R.; de Herder, W.W.; Boeve, E.R.; Visser, T.J.; de Greef, W.J. Renal clearance of the thyrotropin-releasing hormone-like peptide pyroglutamyl-glutamyl- prolineamide in humans. J. Clin. Endocrinol. Metab., 1997, 82, 3068-3073.
25. Sakamoto, H.; Hatano, K.; Higashi, Y.; Mine, Y.; Nakamoto, S.; Tawara, S.; Kamimura, T.; Matsumoto, F.; Kuwahara, S. Animal pharmacokinetics of FK037, a novel parenteral broad-spectrum cephalosporin. J. Antibiot. (Tokyo), 1993, 46, 120-130. (Pubitemid 23075323)
26. Hui, L.; Leung, K.; Chen, H.M. The combined effects of antibacterial peptide cecropin A and anti-cancer agents on leukemia cells. Anticancer Res., 2002, 22, 2811-2816.
27. Gura, T. Innate immunity. Ancient system gets new respect. Science, 2001, 291, 2068-2071. (Pubitemid 32224419)
28. Chen, J.; Falla, T.J.; Liu, H.; Hurst, M.A.; Fujii, C.A.; Mosca, D.A.; Embree, J.R.; Loury, D.J.; Radel, P.A.; Cheng Chang, C.; Gu, L.; Fiddes, J.C. Development of protegrins for the treatment and prevention of oral mucositis: structure-activity relationships of synthetic protegrin analogues. Biopolymers, 2000, 55, 88-98.
29. Ge, Y.; MacDonald, D.; Henry, M.M.; Hait, H.I.; Nelson, K.A.; Lipsky, B.A.; Zasloff, M.A.; Holroyd, K.J. In vitro susceptibility to pexiganan of bacteria isolated from infected diabetic foot ulcers. Diagn. Microbiol. Infect. Dis., 1999, 35, 45-53.
30. Navon-Venezia, S.; Feder, R.; Gaidukov, L.; Carmeli, Y.; Mor, A. Antibacterial properties of dermaseptin S4 derivatives with in vivo activity. Antimicrob. Agents Chemother., 2002, 46, 689-694. (Pubitemid 34157652)
31. Bower, M.A.; Cudic, M.; Campbell, W.; Wade, J.D.; Otvos, L., Jr. Walking the fine line between intracellular and membrane activities of antibacterial peptides. Lett. Pept. Sci., 2003, 10, 463-473.
32. Powers, J.P.; Hancock, R.E. The relationship between peptide structure and antibacterial activity. Peptides, 2003, 24, 1681-1691. (Pubitemid 38198075)
33. Cassone, M.; Frith, N.; Vogiatzi, P.; Wade, D. J.; Otvos, J. L. Induced resistance to the designer proline-rich antimicrobial peptide A3-APO does not involve changes in the intracellular target DnaK. Int. J. Pept. Res. Ther., 2009, 15, 121-128.
34. Fluit, A.C.; Jones, M.E.; Schmitz, F.J.; Acar, J.; Gupta, R.; Verhoef, J. Antimicrobial resistance among urinary tract infection (UTI) isolates in Europe: results from the SENTRY Antimicrobial Surveillance Program 1997. Antonie Van Leeuwenhoek, 2000, 77, 147-152. (Pubitemid 30160414)
35. Lorian, V. Antibiotics in Laboratory Medicine. Williams and Wilkins: Philadelphia, PA, 1996.
36. Otvos, L., Jr.; Cassone, M.; Inacio, V.D.O.; Noto, P.; Rux, J.J.; Wade, J.D.; Cudic, P. In: Peptides for Youth; Escher, E.; Lubell, W.D.; Valle S.D., Ed.; American Peptide Society: San Diego, 2009, pp. 345-377.
37. Credito, K.; Lin, G.; Koeth, L.; Sturgess, M.A.; Appelbaum, P.C. Activity of levofloxacin alone and in combination with a DnaK inhibitor against gram-negative rods, including levofloxacin-resistant strains. Antimicrob. Agents Chemother., 2009, 53, 814-817.
38. Byl, B.; Clevenbergh, P.; Kentos, A.; Jacobs, F.; Marchant, A.; Vincent, J.L.; Thys, J.P. Ceftazidime- and imipenem-induced endotoxin release during treatment of gram-negative infections. Eur. J. Clin. Microbiol. Infect. Dis., 2001, 20, 804-807.
39. Stubbings, W.; Bostock, J.; Ingham, E.; Chopra, I. Mechanisms of the post-antibiotic effects induced by rifampicin and gentamicin in Escherichia coli. J. Antimicrob. Chemother., 2006, 58, 444-448. (Pubitemid 44294963)
40. Renneberg, J.; Walder, M. Postantibiotic effects of imipenem, norfloxacin, and amikacin in vitro and in vivo. Antimicrob. Agents Chemother., 1989, 33, 1714-1720. (Pubitemid 19239162)
41. Sang, Y.; Blecha, F. Antimicrobial peptides and bacteriocins: alternatives to traditional antibiotics. Anim Health Res Rev, 2008, 9, 227-235.
42. Scocchi, M.; Luthy, C.; Decarli, P.; Mignogna, G.; Christen, P.; Gennaro, R. The proline-rich antibacterial peptide Bac7 binds to and inhibits in vitro the molecular chaperone DnaK. Int. J. Pept. Res. Ther., 2009, 15, 147-156.
43. Kruse, T.; Christensen, B.; Raventos, D.; Nielsen, A.K.; Nielsen, J.D.; Vukmirovic, N.; Kristensen, H.-K. Transcriptional profile of Escherichia coli in response to Novispirin G10. Int. J. Pept. Res. Ther., 2009, 15, 97-106.